Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the ...

Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic ...

Hepatitis D virus (HDV) infects the liver and causes severe inflammation. According to WHO estimates, 12 million people ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Our lead program and current focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat hepatitis C virus.

HBV=hepatitis B virus. HBVDR=HBV drug resistance ... 78 new classes of antiviral agents are in trials (eg, small interfering RNA, capsid assembly inhibitors, and immunotherapies). 79 In most cases, ...

He was living with hepatitis B (HBV) and with advanced HIV. "Since both viruses are bloodborne and transmitted in similar ways, coinfections can be quite common," says Dr. Anchalee Avihingsanon ...

Many people can have hepatitis B for decades without needing antiviral treatment. This is because their immune system is effective at suppressing the virus. But the virus can suddenly reactivate ...

2024). However, few studies have focused on the pregnant and postpartum patients with hepatitis B virus infection. In this study, we described the distribution of pgRNA levels in the pregnant and ...

However, its role in hepatitis B virus (HBV) replication has not been previously studied. In this study, we demonstrate that RNF5 effectively inhibits HBV replication by promoting the degradation of ...